Dr Kei Muro talks to ecancer at the 2013 European Cancer Congress about the results from the ASPECT study and FIRE3 trial.

The trial investigated cetuximab vs bevacizumab in patients with KRAS wild-type tumours and whether or not biomarkers will become more important in selecting treatment for colorectal cancer.

Dr Muro also looks at the use of panitumumab in Japan in colorectal cancer, which is uncommon in other countries. According to the ASPECT study, anti-EGFR antibodies have the same trend.

More insight on FIRE3 here